Understanding the molecular mechanisms that mediate the degradation and transmission of tau by AELN has a significant impact on the therapeutic interventions for different Tauopathies (Nixon, 2013; Li and Götz, 2017; Boland et al., 2018). This evidence concerns the gene MAPT and tauopathy.